AGP Picks
View all

AGP Executive Report

Your go-to archive of top headlines, summarized for quick and easy reading.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

Hemp THC Showdown: GOP senators are threatening to block government funding legislation that delays next month’s scheduled ban on hemp-derived THC products. A bipartisan Sheehy-Klobuchar bill would instead keep them legal under new rules, but faces opposition from lawmakers who say the products pose health risks. Patient Access: Boots has launched a doctor-led medical cannabis service for eligible UK adults with chronic pain, anxiety or insomnia. Georgia patients can now also order prescribed cannabis for delivery by mail, while a Texas provider has added same-day pickup in Fort Worth. Product Safety: California cannabis labs say a costly machine intended to detect pesticides failed to reliably identify some harmful chemicals; several have sued its manufacturer. Health Research: A study linked cannabis use disorder with higher odds of suicidal thoughts, adding to concerns about problematic use.

Patient Access: Georgia medical cannabis patients can now order qualifying products online for USPS delivery, expanding access for people who cannot easily reach a dispensary. Hemp Rules: A bipartisan bill from Sens. Tim Sheehy and Amy Klobuchar proposes federal guardrails for hemp-derived CBD and THC products as businesses brace for new restrictions due Dec. 11; supporters say regulation could avert a broad ban. UK Care: Boots is launching private medical cannabis prescriptions for conditions including pain, anxiety and insomnia, a first for a British high-street pharmacy. Mental Health Research: A study of 745 adults found cannabis users improved as much as non-users during transcranial magnetic stimulation for depression, with self-reported use declining during treatment. Safety Watch: New research also links cannabis use disorder with higher odds of suicidal thoughts, underscoring concerns around problematic use.

Medical Cannabis Access: Boots has launched the UK’s first high-street pharmacy service for private medical cannabis prescriptions, for patients 25 and older with chronic pain, anxiety or insomnia who haven’t had enough relief from conventional treatments. Prescriptions require specialist assessment and independent review. Hemp Policy: A federal limit due to take effect Dec. 11 could pull many hemp-derived THC products from US shelves. Wisconsin hemp businesses are bracing for the impact as incoming Democratic leaders pledge to pursue legalization. CBD Research: Australia’s Avecho Biotechnology has resumed recruitment for the final group in its late-stage trial of a CBD capsule for insomnia, a step toward a possible registration application. Pain Research: MIRA Pharmaceuticals reported preclinical findings for its CB2-focused candidate MIRA-55, including pain relief and reduced inflammation without significant THC-like motor effects; it is still investigational. Mental Health: A study of more than 415,000 US adults found cannabis use disorder was associated with 57% higher odds of suicidal thoughts, underscoring the need for care and support.

UK Access: Boots has launched SureLeaf, a private medical cannabis service for patients aged 25+ with eligible chronic pain, anxiety or insomnia who have not found relief from conventional treatments. Prescriptions require specialist assessment and independent review. Hemp Product Rules: A federal law taking effect Dec. 11 could remove many hemp-derived THC products from U.S. shelves by capping THC at 0.4 milligrams per container. Patients say the change may also cut off products they use to manage chronic symptoms. CBD Research: Australian biotech Avecho has resumed recruitment for the final group in its late-stage trial of a CBD capsule for insomnia; a successful result could support a registration application. Health and Safety: A study of more than 415,000 U.S. adults found cannabis use disorder was associated with 57% higher odds of suicidal thoughts. The association persisted over a decade, but does not establish cause and effect. Separately, Colorado research found only one in seven cannabis products carried all required label information.

Medical Cannabis Access: Boots has launched SureLeaf, a private online service for UK patients aged 25 and over with chronic pain, anxiety or insomnia who haven’t found relief from conventional treatments. Prescriptions require specialist assessment, independent review and ongoing monitoring; a University of Nottingham partnership will study patient outcomes for chronic pain. Workplace Health: A CDC-funded University of Oklahoma study will investigate respiratory and other exposure risks for medical cannabis workers, including dust from trimming and manufacturing. Mental Health: A study of more than 415,000 U.S. adults found cannabis use disorder was associated with 57% higher odds of suicidal thoughts from 2014 to 2023. The association is not proof of cause, but researchers say it warrants attention. Hemp Rules: Federal THC limits due to take effect Dec. 11 could sharply restrict hemp-derived products and threaten small businesses, including sellers of some CBD products. A Milwaukee retailer says the new cap is far below the THC levels in many products currently on shelves.

Hemp Rules: Federal restrictions due Dec. 11 could sharply limit hemp-derived products, including some CBD goods and THC beverages. Small businesses warn of closures, while consumers fear losing products they rely on. Sleep and Cannabis: A 35-year study found cannabis users had poorer sleep quality, challenging its use as a sleep aid. A separate opinion piece argues hemp gummies helped one woman’s decades-long insomnia and warns restrictions could disrupt access. Medical Cannabis: One study found patients using medical cannabis were twice as likely to stop prescription opioids; cancer patients have also reported symptom relief, though the findings don’t prove cannabis caused these outcomes. CBD Research: A popular cannabis supplement showed inconsistent anti-inflammatory effects in brain cells, underscoring that benefits remain uncertain.

Hemp Restrictions: Federal rules set to take effect Dec. 11 could make about 95% of hemp-derived products illegal by capping total THC at 0.4 milligrams per container. Small businesses are bracing for losses, while a 76-year-old insomniac says hemp gummies have helped her sleep and urges Congress to protect access. Sleep Research: A 35-year study found cannabis users had poorer objectively measured sleep, challenging the belief that marijuana improves rest. Cannabinoid Safety: New lab research found CBG’s effects on brain immune cells varied by dose: higher concentrations caused cell damage, and lower doses did not reliably reduce inflammation. The findings are preliminary and do not establish effects in people.

Sleep Research: A 35-year study found cannabis users had poorer objectively measured sleep, even though they didn’t report sleeping worse—challenging its use as a sleep aid. CBD and Hemp Rules: Federal restrictions taking effect Dec. 11 cap finished hemp products at 0.4 milligrams of total THC per container. Industry estimates suggest most current hemp-derived products could be affected, and Missouri businesses are already clearing shelves or closing. Cannabinoid Safety: Laboratory research found cannabigerol’s effects on brain immune cells varied by dose; higher concentrations damaged cells, and lower doses did not reliably reduce inflammation. The findings are preliminary, not proof of harm in people. Medical Cannabis: A study reports patients using medical cannabis were twice as likely to stop prescription opioids, while another found cancer patients said cannabis helped ease symptoms. Heart Health: A large U.S. survey linked occasional cannabis use with higher stroke odds, adding to concerns about possible cardiovascular risks.

Hemp Restrictions: Federal limits taking effect Dec. 11 would cap finished hemp products at 0.4 milligrams of total THC per container; industry estimates suggest about 95% of current products could be affected. Missouri’s separate restrictions are already driving hemp shops to clear shelves, with some businesses closing. Medical Cannabis: A study found patients using medical cannabis were twice as likely to stop prescription opioids, an association that does not establish cause and effect. Health Research: A large U.S. survey also linked occasional cannabis use with higher odds of stroke, underscoring the need for more research and informed clinical guidance.

Hemp Rules Tighten: Missouri’s new law bars many hemp-derived THC products from sale outside licensed dispensaries, while federal restrictions are set to narrow the market further on Dec. 11. Hemp and CBD retailers warn the changes could force closures and job losses. Patient Access: California’s Foothill River Farms grows high-CBD and THC cannabis and helps provide free or low-cost products to patients who may benefit, including people with cancer and epilepsy. Medical Research: Studies reported this week found medical cannabis patients were more likely to stop prescription opioids and that cancer patients said cannabis eased symptoms; these findings don’t prove cannabis caused the changes. Health Watch: A large U.S. survey linked even occasional cannabis use with higher odds of stroke, underscoring the need for careful discussion of potential risks as well as benefits.

Hemp Rules: Federal restrictions on some hemp-derived cannabinoids took effect Nov. 12, with tighter product limits due Dec. 11. Missouri’s separate rules have already prompted shops to clear shelves or close. CBD businesses warn the federal changes could threaten their products and livelihoods. Patient Access: A new medical cannabis dispensary opened in Staunton, while a Nevada County farm’s compassion program helps provide free or low-cost cannabis to patients in need. Health Research: A large U.S. survey linked occasional cannabis use to higher odds of past stroke than no use, though it cannot show cannabis caused the strokes. Separately, a study found medical cannabis patients were twice as likely to stop prescription opioids.

Hemp Rules: New federal restrictions took effect Nov. 12 for certain synthetic cannabinoids, with broader hemp-product limits due Dec. 11 unless Congress intervenes. Businesses warn the changes could threaten hemp-derived products and livelihoods, though the rules’ impact will depend on product ingredients. Product Safety: A University of Colorado study found only one in seven cannabis products in Colorado carried all required label information; more than half of flower products misstated THC potency. Researchers say clearer, more consistent labels matter for safer use. Medical Cannabis: In a survey of 237 cancer patients, 35 reported using cannabis after diagnosis; most said it eased their main symptom and improved quality of life. Separately, a study of chronic pain patients found those receiving medical cannabis were more likely to stop long-term opioid prescriptions, though the findings show an association, not proof cannabis caused them to stop.

THC-Free CBD: Simple Leaf says its CBD, CBG, CBN and CBC gummies, oils and capsules test non-detectable for THC; that means none was detected at the lab’s testing limit, not necessarily absolute zero. Hemp Policy: Illinois hemp rules could sharply limit a small farm’s CBD business, though a judge has delayed the law. A separate federal THC limit taking effect Dec. 11 could also put many hemp-derived drinks above the allowed threshold. Pain Care: In a study of 8,353 chronic-pain patients, those receiving medical cannabis were two to three times more likely to stop long-term opioid prescriptions than those who did not; the findings show an association, not proof cannabis caused the change. Cancer Care: Among 35 cancer patients who used cannabis after diagnosis, most reported improvement in their main symptom and overall quality of life, underscoring the need for open conversations with clinicians. Heart Health: A large survey study linked occasional cannabis use to 40% higher odds of reporting a prior stroke. The observational findings do not establish cause and effect.

Hemp Rules: Philadelphia’s restrictions on intoxicating hemp products take effect Thursday, while Illinois has delayed its planned hemp ban pending a court hearing. A veterans’ advocate warns a federal restriction due Dec. 11 could also remove nonintoxicating hemp products, including CBD, that some veterans use. Research and Policy: A Senate committee urged the VA to study whether medical cannabis access is linked to lower opioid use among veterans. Newly elected GOP leaders oppose marijuana reform as the Trump administration advances rescheduling. Health Watch: A study linked even occasional marijuana use to 40% higher odds of stroke; the finding shows an association, not proof that cannabis caused the strokes. Consumer Caution: A cancer patient writing to the Los Angeles Times described costly CBD oil that did not help and relayed concerns about contamination in poorly monitored products.

Heart Health: New research involving more than 440,000 U.S. adults linked even occasional cannabis use with 40% higher odds of stroke; the findings are preliminary and show an association, not proof of cause. A separate UCLA study found occasional users who were men reported stronger effects, including anxiety and a faster heart rate, than women. Hemp & CBD Rules: Federal restrictions due Dec. 11 threaten many hemp-derived products, with one Kansas CBD shop closing as sales fall. Illinois has agreed to pause enforcement of its hemp law against the businesses suing until Nov. 19, pending a court hearing. Medical CBD: MediPharm Labs launched an ANVISA-authorized full-spectrum CBD oil in Brazil for medicinal use. Cannabis Policy: Texas lawmakers filed bills to legalize and regulate adult-use cannabis, while North Carolina Democrats say they may pursue medical cannabis or decriminalization next year.

Hemp Rules: Illinois agreed to pause enforcement of its new hemp law against the businesses suing the state until Nov. 19, as a court considers their challenge. Separately, federal restrictions due Dec. 11 could limit finished hemp products to 0.4 milligrams of total THC per container, putting many products and Texas businesses at risk. CBD Medicine: MediPharm Labs launched an ANVISA-authorized full-spectrum CBD oral oil in Brazil, made at its Canadian facility under pharmaceutical manufacturing standards. State Policy: North Carolina Democrats say they plan to pursue marijuana legislation next year after winning control of the state House, with medical access and decriminalization among the issues in view. Sleep Research: A 35-year study found cannabis use was associated with poorer measured sleep quality, despite users not reporting that their sleep had worsened.

Medical Cannabis Research: India’s CSIR-IIIM is advancing a project to develop cannabis-based medicines for pain, neuropathies, cancer and epilepsy, with officials describing it as a step toward export-quality treatments. Industry Under Pressure: UK medicinal cannabis supplier Grow Group secured £2 million in new equity and a £10 million debt-for-equity swap, and named Clare Holliday and Pierre van Weperen as co-CEOs. Meanwhile, a federal hemp measure due Dec. 11 could remove many hemp-derived products from the U.S. market, threatening CBD-focused growers; Illinois’ ban on intoxicating hemp products is due to begin Thursday. Health Watch: Recent studies linked cannabis use to higher mortality among people with alcohol-associated hepatitis and to increased stroke and cardiovascular risks. The findings show associations, not proof that cannabis caused the outcomes.

Health Research: A multinational study of 800 people hospitalized with alcohol-associated hepatitis found active cannabis use was linked to 2.5 times the risk of death; researchers recommend screening and treatment for substance use. Medical Research: India’s CSIR-IIIM Jammu is advancing research into cannabis-based medicines for pain, cancer, epilepsy, neuropathy and severe respiratory distress, with preclinical trials planned. Hemp Policy: Willie Nelson is urging Congress to regulate rather than ban hemp-derived products before the federal ban takes effect Dec. 11, warning it could harm farmers and patients. Patient Access: Kentucky’s medical cannabis program has passed 30,000 registered patients, while Moab’s first medical cannabis pharmacy plans to open Nov. 13. Heart Health: Recent studies have also linked cannabis use with higher stroke and cardiovascular risks, adding to concerns about potential harms.

Health Risks: A multinational study of 800 hospitalized patients found active cannabis use independently predicted death among people with alcohol-associated hepatitis; cannabis users had 2.5 times the odds of dying, even after researchers adjusted for disease severity. The findings show an association, not proof that cannabis caused the deaths. Heart and Stroke: Recent studies also link cannabis use with higher odds of stroke and cardiovascular disease, adding to concerns about potential health risks. Teen Care: Cannabis appeared in 84% of substance-related emergency and hospital encounters among 16- to 18-year-olds in a WashU study—but that does not mean cannabis caused each visit. Medical Research: Jammu’s cannabis medicine project is moving toward preclinical trials, exploring treatments for pain, cancer, epilepsy and other conditions. Hemp Rules: A looming federal ban on intoxicating hemp products has Illinois businesses suing to block the state ban, as sellers face growing uncertainty.

Teen Health: Cannabis appeared in 84% of substance-related emergency visits among 16- to 18-year-olds in a WashU study, but researchers caution it was listed in patients’ records—not necessarily the reason for care. Health Risks: New studies link cannabis use with higher odds of stroke and cardiovascular disease; another finds daily use and cannabis use disorder more common among people using multiple product types. Hemp Rules: A federal ban on hemp-derived THC products is looming, while Illinois businesses are suing to block a state ban and Missouri’s attorney general is pursuing retailers over alleged unlicensed cannabis sales. CBD Labeling: The EU’s top court ruled that foods containing CBD cannot be labeled organic. Medical Access: Kentucky’s medical cannabis program has passed 30,000 cardholders, and Massachusetts lawmakers approved a bill allowing military veterans to access medical cannabis without a doctor’s recommendation.

Sign up for:

Medical Bud News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Medical Bud News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.